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ABSTRACT
Background.We investigated whether a brief geriatric as-
sessment (GA) would identify important patient deficits
that could affect treatment tolerance and care outcomes
within a sample of older cancer patients rated as functionally
normal (80%–100%) on the Karnofsky performance status
(KPS) scale.
Methods. Cancer patients aged $65 years were assessed
using a brief GA that included both professionally and patient-
scored KPS and measures of comorbidity, polypharmacy,
cognition, function, nutrition, and psychosocial status. Data
were analyzed using descriptive statistics and multivariable
logistic regression.
Results. The sample included 984 patients: mean age was 73
years (range: 65–99 years), 74% were female, and 89% were
white. GA was conducted before (23%), during (41%), or after
(36%) treatment. Overall, 54% had a breast cancer diagnosis
(n 5 528), and 46% (n 5 456) had cancers at other sites.
Moreover, 81% of participants (n 5 796) had both pro-
fessionally and self-rated KPS $80, defined as functionally
normal, and those patients are the focus of analysis. In this
subsample, 550 (69%) had at least 1 GA-identified deficit, 222
(28%) had 1 deficit, 140 (18%) had 2 deficits, and 188 (24%)
had $3 deficits. Specifically, 43% reported taking $9
medications daily, 28% had decreased social activity, 25%
had$4 comorbidities, 23% had$1 impairment in instrumen-
tal activities of daily living, 18% had a Timed Up and Go
time $14 seconds, 18% had $5% unintentional weight loss,
and 12% had a Mental Health Index score#76.
Conclusion.Within this sample of older cancer patients who
were rated as functionally normal by KPS, GA identified
important deficits that could affect treatment tolerance and
outcomes. The Oncologist 2015;20:379–385
Implications for Practice: The optimal evaluation to guide treatment decisions for older cancer patients is not known. The
Karnofskyperformance status (KPS) scale is frequently used toguideoncology practice,whereas the standard in geriatricmedicine
is the comprehensive geriatric assessment (GA). Comprehensive GA is time and resource intensive and impractical in routine
cancercare.This studyshowsthatabrief,mostlypatient-administeredGAcan identifydeficits thatcouldaffecttreatmenttolerance
andoutcomes in patients assessed as functionally normal byKPS. AbriefGA should be incorporated into routineoncology practice
for timely identification of patient deficits that may be remediable before or during treatment.
INTRODUCTION
Cancer isadiseaseofaging. In theU.S., 53%ofcancer incidence
and 69% of cancer mortality occurs in persons aged$65 years
[1].With theaging of theU.S. population and theproportionof
adults aged$65 years expected to double by 2060 (20%) [2],
cancer incidence is projected to increase from 1.6 million in
2010 to 2.3 million in 2030 [3]. These trends underscore the
pressing fact that care of the older patient will become an
essential component of all oncology practices and a significant
challenge for clinicians with limited expertise in geriatrics [4].
Evaluation of older patients can be especially challenging
because traditional considerations of chronological age and
tumor characteristics alone do not capture the rangeof fitness
and frailty among those aged$65years [5–7]. Instead, there is
growing recognition that “functional age” is a more accurate
Correspondence: Trevor A. Jolly, M.D., 170Manning Drive, CB# 7305, Chapel Hill, North Carolina 27599, USA.Telephone: 919-966-3856; E-Mail:
trevor_jolly@med.unc.edu Received June 27, 2014; accepted for publication December 18, 2014; published Online First on March 12, 2015.
©AlphaMed Press 1083-7159/2015/$20.00/0 http://dx.doi.org/10.1634/theoncologist.2014-0247
TheOncologist 2015;20:379–385 www.TheOncologist.com ©AlphaMed Press 2015
indicator of cancer treatment tolerance because functioning
varies widely among older cancer patients of similar chro-
nological age [8, 9]. Introduced in 1948, the Karnofsky per-
formance status (KPS) scale [10–13] was the earliest effort to
introduce baseline functional status as a core consideration in
treatment decisions for cancer patients, specifically with
regard to chemotherapy. Traditionally, KPS was assessed by
health professionals. KPS is a composite measure that takes
into consideration the patient’s physical ability to engage in
normal activities of daily living (ADLs), work, and care of
personal needs. Professionals rate patients on a global scale
from 20 (“very sick, hospital admission necessary, active
supportive treatment necessary”) to 100 (“normal, no com-
plaints, no evidence of disease”). Patients scored between 80
and 100 are considered functionally normal because they are
“able to carry on normal activity and to work and no special
care is needed,” whereas scores between 50 and 70 describe
patients who are “unable to work but able to live at home and
care formostpersonalneedswithvaryingamountsofassistance
needed” [10–12]. In patients ratedbetween 10 and40,“disease
may be progressing rapidly,” and these patients are considered
“unable to care for self” and likely require the equivalent of
institutional or hospital care [10–12]. A patient-assessed KPS
(Patient-KPS) that mirrors the professionally assessed KPS has
been developed to provide independent prognostic informa-
tion [14, 15]. Studies have found that patient self-assessments
may differ from professional assessments, with patients
reporting generally lower physical function [16, 17]. In a study
of patients with advanced lung or colorectal cancer, for
example, the authors reported 67% disagreement between
KPS and Patient-KPS scores and concluded that physician
overestimation of performance status may lead to treatment
decisions that compromise survivorship [16].
In oncology practice, performance status has been shown
to be a reliable and consistent determinant of prognosis in
several major tumor types and among patients of all ages [11,
14, 15]. The currently accepted standard for the evaluation
of older patients in general is the comprehensive geriatric
assessment (GA), which covers multiple domains (medical,
psychological, functional) and is traditionally performed by
a multidisciplinary team that includes a geriatrician, a nurse,
and a social worker [18–20]. The comprehensive GA includes
assessment of functional status by determining a patient’s
ability to performADLs [21, 22], such as bathing, dressing, and
toileting, and instrumental activities ofdaily living (IADLs) [21],
such as shopping, financial management, and medication
management. Baseline assessment of function using a variety
ofmeasures is particularly important for older cancer patients
because they are likely to have functional deficits that could
affect prognosis and survival, treatment tolerance, and quality
of life during and after treatment and that may be modifiable
before or during treatment [20, 23].
To encourage GA in clinical practice—and to address the
dual issues of inadequate time (approximately 2 hours) and
inadequate expertise (training in geriatrics) that would be
required for comprehensive GAs to be conducted in busy
oncology clinics—a brief GA has been developed and tested in
clinical trials and oncology practice [20, 24]. This brief GA
includes both the KPS and the Patient-KPS and other vali-
dated and reliable measures of function that are especially
informative in assessing functional age and treatment toler-
ance of older cancer patients [25–27].
The primary goal of this study was to investigate whether
GA measures beyond KPS and Patient-KPS would identify
important patient impairments or deficits that could poten-
tially affect treatment tolerance and care outcomes among
patients who were rated as functionally normal based on a KPS
rating of $80 by both the health care professional and the
patient. We focused our analysis on this group with both self-
rated and professionally rated KPS in the normal range to
eliminate any confounding in GA results that may reflect dis-
agreement in KPS scoring between patients and professionals.
MATERIALS AND METHODS
Patients
This study includes patients who consented to enroll in
Carolina Senior (Lineberger Comprehensive Cancer Center
protocol 0916; ClinicalTrials.gov identifier NCT01137825),
a registry of English-speaking cancer patients aged$65 years
who completed a brief GA [24, 28, 29]. Participants were
recruited fromclinicsat theNorthCarolinaCancerHospital and
the University of North Carolina at Chapel Hill (UNC) Cancer
Network of affiliated clinics in the community [30]. Written
informed consent was obtained from all study participants.
The study protocol was approved by the UNC Lineberger
ComprehensiveCancerCenterprotocol reviewcommitteeand
the UNC institutional review board.
Brief Geriatric Assessment
TheGAused for Carolina Senior was developed by Hurria et al.
and is composed of validated and reliable measures within
domains typically assessed by geriatricians: function, comor-
bidity, cognition,nutrition,andpsychosocial status [24,28,29].
Table 1 shows assessments conducted by trained research or
clinical staff and measures reported by patients. The patient-
reported component of the GA was completed either in clinic
(46% of participants) or at home (54%), with the completed
questionnaire mailed back to the data manager in a self-
addressed, stamped envelope [30]. The average amount of
time for completing the brief GA is 10 minutes for the
professionally assessed items and 20 minutes (range: 15–28
minutes) for the patient-reported items [30].
The KPS [10–13] and the Patient-KPS [15] have been
described.The Timed Up and Go (TUG) test asks the patient to
standup froma chair, walk adistance of approximately 10 feet,
turn, walk back to the chair, and sit down; total seconds
required to complete the test are recorded or “inability to
complete” is noted [31, 32].The BlessedOrientation-Memory-
Concentration (BOMC) test [33, 34] assesses whether the
patient knows the current year, month, and time of day and
asks the patient to count backward from 20 to 1, to recite the
months in reverse order, and to repeat a memory phrase. The
IADL scale [21] inquires about the amount of assistance the
patient requires inusing the telephone, getting toplacesoutof
walking distance, shopping for groceries or clothes, preparing
meals, doing housework, taking medications, and handling
money, with response options of 2 (“without help”), 1 (“with
some help”), and 0 (“completely unable”). The physical
©AlphaMed Press 2015
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function scale [35] inquires about limitations in engaging in
various activities (listed in Fig. 1), with response options of 2
(“notatall limited”), 1 (“limiteda little”), and0 (“limiteda lot”).
The social support measure [36] includes 12 items inquiring
about whether the patient has someone who is supportive in
a variety of ways, such as taking the patient to the doctor,
helpingwith daily chores, providing good advice about a crisis,
or listening when the patient needs to talk, with response
options ranging from 0 (“none of the time”) to 4 (“all of the
time”). The full scale has 20 questions and 4 subscales; the
tangible and emotional/information subscales were used for
analysis.The social activity measure [37] consists of four items
that inquire about how physical health or emotional problems
orconditionshave interferedwith social activities (e.g., visiting
with friends, relatives, neighbors, groups) over the past 4
weeks (two scales: “all of the time” to “none of the time” and
“not at all” to “extremely”), have affected the patient’s usual
level of social activity over the past 6 months (“much less” to
“muchmore” socially active), and have limited social activities
compared with others of comparable age (“much more” to
“much less” limited than others). The Mental Health Index
(MHI-5) includes five items [38–40] thatmeasurehowmuchof
the time the patient was happy, calm or peaceful, nervous,
downhearted or blue, and “so down in the dumps that nothing
could cheer you up.”On a 6-point scale pertaining to “the past
two weeks,” MHI-5 response options range from “all of the
time” to “noneof the time.”A total scorewas calculatedbased
on the average of items answered, after reverse coding, and
then converted to a scale of 0–100 points, with higher scores
indicating better mental health.
For thepurposesofour study, variablesweredichotomized
at cut points (Table 1) that signal patient impairments or
deficits that should be considered in treatment decisions. All
cut points were derived from a review of the literature, with
references cited in the measures column of Table 1. A TUG
score of $14 seconds, for example, is predictive of falls [33],
and increased time to complete the TUG test is predictive of
risk of early death among older patients receiving chemother-
apy treatment [46]. Falls are of concern among adults aged
$65 years because unintentional injury is the seventh leading
cause of death and falls make up 54% of unintentional injuries
[47]. A cutpointof#76 indicates that a patient has poormental
health [40, 48], anda score$11on theBOMC test is considered
abnormal [49]. For this study,patientswereconsideredeitherat
risk or not at risk, depending on each cut point.
Statistical Analysis
Between October 2009 and August 2013, 1,088 cancer
patients aged$65 years were enrolled in the Carolina Senior
registry and completed the brief GA.Of these, 984haddata for
both KPS and Patient-KPS, and they compose the final sample
for this study. Descriptive statistics are provided asmeans and
ranges or as frequencies and percentages, along with exact
binomial 95%confidence intervals (CIs). Formeasures inwhich
the total score was calculated as a sum (physical function,
IADLs, BOMC, social support), only patients with complete
Table 1. Brief geriatric assessment domains and measures
Domains Measures Score range Dichotomized
Professionally assessed
Function Timed Up and Go [31, 32] Timed (seconds); higher
score→ lower functioning
,14 seconds,$14 seconds,
or unable to complete




Concentration test [33, 34]
0–28; higher score→ lower
cognition
,11,$11
Body composition Body mass index [41] No upper or lower limit
Patient reported
Function Physical function [35] 0–20; 205 not at all limited ,20, 20
Instrumental activities
of daily living [21]
0–14; 145 can do without help #14, 14
Patient-reported KPS [15] 30–100; higher score→ better
functioning
,60, 60–70,$80
Number of falls in the
past 6 months [42]
$2,,2
Comorbidity Number of medications [43] $4,,4
Number of comorbidities [44] $9,,9
Psychological Five-itemMental Health Index [38–40] 0–100; higher score→ better
mental health
#76,.76
Social (MOS) MOS Social Activity Limitation [37] 0–100; higher score→more
limitations
MOS Social Support Survey [36]
(Tangible and Emotional/
Informational Support subscales)
0–100; higher score→ better
support
Nutrition Unintentional weight loss in




Abbreviations: KPS, Karnofsky performance status; MOS, Medical Outcomes Survey.
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data received a score. For the MHI-5 and social activity
limitations, scores were calculated if more than half of the
items were answered [38–40]. A multivariable logistic re-
gressionmodelwasusedtoevaluatetheeffectofdemographic
and clinical characteristics on the outcome of having any
deficits compared with no deficits. SAS statistical software
version 9.3 (SAS Institute Inc., Cary, NC, http://www.sas.com)
was used for all analyses.
RESULTS
Sample Characteristics, KPS Scores, and Patient-
KPS Scores
Of the full sample of patients in the database (n5 984), 91%
(n5893)wereprofessionally ratedas functionallynormal (KPS
$80) and 84% (n 5 828) rated themselves as functionally
normal (Patient-KPS$80). For81%ofpatients (n5796), there
was agreement between patients and health professionals on
aKPS rating$80 (Table2), and this subsample is the focusof all
remaininganalyses. Characteristicsof the full sample (n5984)
and the subsample (n5 796) are compared in Table 3.
GA-Identified Deficits
To assess whether the GA identifies important deficits among
patients rated as KPS $80, we calculated the proportion of
study participants at clinically important cut points in seven
functional domains: TUG scores$14 seconds,$2 falls in the
past 6 months, decreased social activity, IADL score ,14
(i.e., impairment of 1 activity or more), unintentional weight
loss$5% in the past 6 months, BOMC score$11, and MHI-5
score #76. Our findings are presented in Figure 2. Among
participants, 28% (95% CI: 25.3%–31.7%; n 5 225) reported
decreased social activity resulting from physical or mental
health problems, 23% (95% CI: 19.9%–25.9%; n 5 180)
reported impairment in at least 1 IADL, 18% (95% CI:
15.5%–21.0%; n5 144) had TUG scores$14 seconds or were
unable to complete, 7% (95% CI: 55.6%–9.4%; n5 57) had$2
falls, 18% (95% CI: 15.4%–20.9%; n 5 143) reported $5%
unintentional weight loss, and 12% (95% CI: 9.6%–14.6%;
n5 84) had an MHI-5 score of#76. In addition to these GA-
identified deficits, 43% (95% CI: 39.5%–47.4%; n 5 273)
reported taking $9 medications daily, and 25% (95% CI:
21.5%–27.9%; n5 177) had$4 comorbidities.
We calculated total GA-identified deficits per patient
(Fig. 3), using the above-listed seven measures. Within our
“normal”KPSsubsample,222 (28%;95%CI: 24.8%–31.1%)had
1 GA-identified deficit, 140 (18%; 95% CI: 15.0%–20.4%) had 2
deficits, 114 (14%; 95%CI: 12.0%–16.9%)had3deficits, and48
(6%; 95% CI: 4.5%–7.9%) had 4 deficits. Overall, 69% (95% CI:
65.8%–72.3%; n5 550) had at least 1 deficit.
Physical Function Limitations
Figure 1 shows the proportion of study participants who
reported they were limited a lot in their ability to perform
variousphysical functions.Overall, 41%(95%CI:37.8%–44.8%;
n 5 323) reported they were very limited by their health in
engaging in vigorous activities such as running, lifting heavy
objects, or participating in strenuous sports. Moreover, 23%
(95% CI: 19.7%–25.6%; n5 178) were limited by their health in
walking.1mile,11%(95%CI:8.9%–13.4%;n587)were limited
in walking several blocks, and 13% (95% CI: 10.9%–15.7%;
n5 104) were limited in climbing several flights of stairs.
Social Activity Limitations
When asked how their level of social activity during the past 6
months compared with their usual level of activity, 28% (95%
CI: 25.3%–31.7%; n 5 225) of participants reported being
somewhat or much less socially active than before (Fig. 4). In
addition 13% (95% CI: 10.8%–15.6%; n5 103) reported being
“somewhat or much more limited” in their social activities
because of their physical health or emotional problems
compared with others of similar age.




£50 60–70 80–100 Total
Patient- rated KPS
#50 8 (0.8) 3 (0.3) 8 (0.8) 19 (2)
60–70 10 (1) 38 (4) 89 (9) 137 (14)
80–100 4 (0.4) 28 (3) 796 (81) 828 (84)
Total 22 (2) 69 (7) 893 (91) 984 (100)
Abbreviation: KPS, Karnofsky performance status.







Time of assessment, n (%)
Before treatment 224 (23) 173 (22)
During treatment 407 (41) 312 (39)
After treatment 351 (36) 309 (39)
Female, n (%) 730 (74) 603 (76)
Age, mean (range) 73 (65–99) 72 (65–99)
Race, n (%)
White 877 (89) 727 (91)
Black 100 (10) 64 (8)
Other 7 (1) 5 (1)
Education, n (%)
Some high school 65 (7) 37 (5)
High school degree 413 (42) 318 (40)
Associate or bachelor degree 319 (32) 273 (34)
Advanced degree 185 (19) 166 (21)
BMI, mean (range) 27 (15–64) 27 (15–50)
Tumor type, n (%)
Breast 528 (54) 452 (57)
Lung 99 (10) 67 (8)
Lymphoma 61 (6) 50 (6)
Leukemia 49 (5) 38 (5)
Colorectal 44 (4) 36 (5)
Head and neck 43 (4) 35 (4)
Other 159 (16) 117 (15)
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Social Support
Fourteen percent (95% CI: 11.3%–16.2%; n 5 107) of
participants reported having little or no support “if confined
to bed.” Nine percent (95% CI: 7.2%–11.3%; n5 72) reported
little or no support for preparing meals if they were unable to
do so or help with daily chores if they were sick (9%; 95% CI:
7.4%–11.6%; n 5 74). Seven percent (95% CI: 4.9%–8.4%;
n551) reported limitedsupport for “sharingyourmostprivate
worriesor fears,”and5%(95%CI: 3.9%–7.1%;n542) reported
limited support with regard to “someone to turn to for
suggestions about how to deal with a personal problem.”
Mental Health
The mean score for the MHI-5 was 87.1 (SD: 10.5; range:
43.3–100), with higher scores indicating better mental health.
Twelve percent of patients (95% CI: 9.6%–14.6%; n5 84) had
MHI-5 scores#76, signifying suboptimalmental health (Fig. 2).
Multivariable Model
A multivariable model for the outcome of having any deficit
included sex, age, race, education, cancer type (breast vs. other),
and treatment stage as covariates. This model showed that
increasingage (p5 .005) andbeing in active treatment, (p5 .01),
which included chemotherapy, radiation, and other forms of
cancer-directed therapyexcludingendocrine therapy,were signif-
icantly associated with having a deficit. The odds ratio for each
5-year increase inagewas1.2 (95%CI:1.06–1.38), suggestingthat
as age increases, so do the odds of having at least 1 deficit. The
odds ratio for active treatment comparedwith pretreatmentwas
1.7 (95% CI: 1.13–2.64), suggesting that patients receiving active
treatment were more likely to have at least 1 GA-identifiable
deficit comparedwithpatientswhohadnotyetbegun treatment.
DISCUSSION
This study analyzed KPS, Patient-KPS, and other GA variables
within a sample of older cancer patients. The primary aim was
to investigate the frequency of deficits in GA measures for
patients with normal function performance status ratings of
$80 on both the KPS and the Patient-KPS.Major impairments
detected through GA in this group could affect treatment
tolerance, outcomes, and health care utilization. Potentially
modifiable deficits should be addressed through interventions
because previous studies have shown that such impairments,
includingahighnumberofcomorbidities,deficiencies in IADLs,
and polypharmacy, can complicate cancer treatment and/or
worsen during cancer therapy [50–52]. Examples of inter-
ventions include medication review in the event of excessive
polypharmacy and physical or occupational therapy in the
event of a recent history of falls.
In our sample of older cancer patients, a high proportion
(81%)werebothprofessionallyandpatient-ratedasfunctionally
normal (KPS $80). We focused our analyses on this subset
because patients with high KPS scores are less likely to be
queried by health care professionals about functional deficits
that might affect goals of care, treatment selection, clinical trial
participation, treatment tolerance, and treatment outcomes.
We found major deficiencies in these patients, including high
proportionsofpatients takingnineormoremedicationsdailyor
having four ormore comorbidities. Comorbidity is independent
from functional status in older adults, and the particular
comorbidity matters greatly in treatment decisions and overall
prognosis fordifferent typesofcancer [50, 53–55]. Inaddition,1
Figure 1. Karnofsky performance status $80, physical function
for patients who scored 0 (“limited a lot”).
Figure 2. Karnofsky performance status $80, geriatric
assessment-identified deficits.
Abbreviations: BOMC, Blessed Orientation-Memory-
Concentration test; IADL, instrumental activities of daily living;
MHI, Mental Health Index; TUG, Timed Up and Go.
Figure 3. Karnofskyperformance status$80, numberofgeriatric
assessment-identified deficits.
Figure 4. Karnofsky performance status $80, social activity
limitations.
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in 5 of our patients required$14 seconds to complete the TUG
test or was unable to complete the test. Higher TUG scores are
associated with higher risk for postoperative complications
among older cancer patients and higher risk of death among
older cancer patients receiving first-line chemotherapy [46].
We found that patients who completed the assessment
during active treatmentweremore likely to report at least one
functional deficit.This findingmay reflect the observation that
cancer therapies themselves can cause toxicities that may
contribute to functional impairments in older cancer patients.
Taxane-based chemotherapy, for example, can precipitate or
worsen pre-existing peripheral neuropathy and result in gait
impairment and falls. Cancer treatments may also exacerbate
pre-existing medical conditions such as diabetes, leading to
pooreroveralloutcomes[56].Thesefindingssuggestthatclinicians
should evaluate and pay close attention to functional deficits in
older cancer patients, especially during active treatment.
Our finding that GA provides important information on
functional and other deficits beyond KPS and Patient-KPS is
supported by prior studies [8, 57]. Our study is novel in that it
focused exclusively on older cancer patients (aged$65 years)
whowere ratedashigh functioning,whereasother studieshave
focused largely on patients with advanced cancer. Our study
underscores the importance of GA for older patients, even
when they are rated as functionally normal with less sensitive
measures such as KPS, because many have deficits that can be
ameliorated by specific interventions or by tailoring treatment
to lower the riskof further functional decline. Our findings both
corroborate prior studies and contribute new insights regarding
the importance of conducting GAs for all older cancer patients,
even among those who appear functionally normal.
Our study has some limitations.We did not collect data on
cancer patients who chose not to participate in the Carolina
Senior registry (34% of the 1,830 patients who were
approached declined to participate), so we were not able to
investigate the potential for self-selection bias by comparing
descriptive characteristicsofparticipants andnonparticipants.
Furthermore, the large proportion of breast cancer patients in
our sample (54%) may limit the applicability of our findings to
the general population of cancer patients in which breast
cancer is less prevalent. This limitation does not diminish our
overallmessage that GA is feasible in busy oncology clinics and
has great value for identifying deficits in KPS-normal cancer
patients. We did not collect information on the type of
treatment planned, under way, or completed, although that
information would have enhanced our investigation. A final
limitation is thatwecollecteddatausingtheMHI-17,whichhas
a“pasttwoweeks” timeframe,butweanalyzedonly theMHI-5
items [40, 48],which have a “pastmonth” time frame, because
we could find empirically justified cut points for theMHI-5 but
not for the MHI-17.
CONCLUSION
ThebriefGAhasbeen shown tobe feasiblewithin the timeand
personnel constraints of busy oncology clinics [5, 30] and can
provide important additional prognostic information, even
when KPS and Patient-KPS indicate functional normality. Only
a third of our functionally normal sample had noGA-identified
deficits.Amongthe28%thathad justoneGA-identifieddeficit,
that single deficit could have had important prognostic
implications, such as TUG score $14 or $5% unintentional
weight loss. Furthermore, the identification of potentially
modifiable deficits provides anopportunity to refer patients to
an allied health care professional or to occupational therapy
(for ADL or IADL deficits), physical therapy (for falls, balance,
gait, muscle strength), dieticians, social workers, or psychiatric
services. Next steps are to investigate implementation of the
brief GA in a variety of clinic settings (university and
community-based clinics) and to evaluate how GA findings
provided to oncologists can affect their treatment decisions
and patient outcomes.
ACKNOWLEDGMENTS
Brittaney-Belle E. Gordon is a medical student at the School of
Medicine, University of North Carolina, Chapel Hill (UNC).This
study was supported in part by the Breast Cancer Research
Foundation, the Lineberger Comprehensive Cancer Center at
UNC, and the UNC Center for Health and Aging. The findings
were previously presented in part as a poster at the American
Geriatric Society (AGS) annual scientificmeeting,May2012, in
Seattle,Washington.
AUTHOR CONTRIBUTIONS
Conception/Design: Trevor A. Jolly, Hyman B. Muss
Provisionof studymaterialorpatients:TrevorA. Jolly, SusanG.Moore,W.Chris
Taylor, Michael Messino, Hyman B. Muss
Collection and/or assembly of data: Trevor A. Jolly, Allison M. Deal, Shani M.
Alston, Brittaney-Belle E. Gordon, SamaraA. Dixon, SusanG.Moore,W. Chris
Taylor, Michael Messino, Hyman B. Muss
Data analysis and interpretation: Trevor A. Jolly, Allison M. Deal, Kirsten A.
Nyrop, Mackenzi Pergolotti, Hyman B. Muss
Manuscript writing: Trevor A. Jolly, Allison M. Deal, Kirsten A. Nyrop, Grant R.
Williams, Mackenzi Pergolotti, Hyman B. Muss
Final approval of manuscript: Trevor A. Jolly, AllisonM. Deal, Kirsten A. Nyrop,
Grant R. Williams, Mackenzi Pergolotti, William A. Wood, Shani M. Alston,
Brittaney-Belle E. Gordon, Samara A. Dixon, Susan G.Moore,W. Chris Taylor,
Michael Messino, Hyman B. Muss
DISCLOSURES
The authors indicated no financial relationships.
REFERENCES
1. SEER stat fact sheets: All cancer sites. Available
at http://seer.cancer.gov/statfacts/html/all.html.
Accessed February 20, 2015.
2. U.S. Census Bureau projections show a slower
growing,older,morediversenationahalfcentury from
now. Available at http://www.census.gov/newsroom/
releases/archives/population/cb12-243.html. Accessed
February 20, 2015.
3. Smith BD, Smith GL, Hurria A et al. Future of
cancer incidence in theUnitedStates: Burdensupon
an aging, changing nation. J Clin Oncol 2009;27:
2758–2765.
4. Hurria A, Naylor M, Cohen HJ. Improving the
quality of cancer care in an aging population: Recom-
mendations from an IOM report. JAMA 2013;310:
1795–1796.
5.Mohile SG, Magnuson A. Comprehensive geri-
atric assessment in oncology. Interdiscip Top
Gerontol 2013;38:85–103.
6. Pal SK, Katheria V, Hurria A. Evaluating the older
patient with cancer: Understanding frailty and the
geriatric assessment. CA Cancer J Clin 2010;60:
120–132.
7. Fried LP, Tangen CM, Walston J et al. Frailty in
older adults: Evidence for a phenotype. J Gerontol A
Biol Sci Med Sci 2001;56:M146–M156.
8. Repetto L, Fratino L, Audisio RA et al. Compre-
hensive geriatric assessment adds information to
Eastern Cooperative Oncology Group performance
status inelderly cancerpatients: An ItalianGroup for




384 Geriatric Assessment-Identified Deficits
9. Extermann M. Studies of comprehensive geri-
atric assessment in patients with cancer. Cancer
Contr 2003;10:463–468.
10. Karnofsky D, Burchenal J. The clinical evalua-
tion of chemotherapeutic agents in cancer. In:
Macleod CM, ed. Evaluation of Chemotherapeutic
Agents. New York, NY: Columbia University Press,
1949:191–205.
11. Schag CC, Heinrich RL, Ganz PA. Karnofsky
performance status revisited: Reliability, validity,
and guidelines. J Clin Oncol 1984;2:187–193.
12. Crooks V,Waller S, Smith T et al.The use of the
Karnofsky Performance Scale in determining out-
comes and risk in geriatric outpatients. J Gerontol
1991;46:M139–M144.
13.Yates JW, Chalmer B, McKegney FP. Evaluation
of patientswith advanced cancer using the Karnofsky
performance status. Cancer 1980;45:2220–
2224.
14. Blagden SP, Charman SC, Sharples LD et al.
Performance status score: Do patients and their
oncologists agree? Br J Cancer 2003;89:1022–1027.
15. Loprinzi CL, Laurie JA, Wieand HS et al. Pro-
spective evaluation of prognostic variables from
patient-completed questionnaires. J Clin Oncol
1994;12:601–607.
16. Schnadig ID, Fromme EK, Loprinzi CL et al.
Patient-physician disagreement regarding perfor-
mance status is associated with worse survivorship
in patients with advanced cancer. Cancer 2008;113:
2205–2214.
17. Dajczman E, Kasymjanova G, Kreisman H et al.
Should patient-rated performance status affect
treatment decisions in advanced lung cancer? J
Thorac Oncol 2008;3:1133–1136.
18. Cohen HJ, Feussner JR,Weinberger M et al. A
controlled trial of inpatient and outpatient geriatric
evaluation and management. N Engl J Med 2002;
346:905–912.
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